Lipocine slumps 10% ahead of Ad Com review for Tlando

|About: Lipocine Inc. (LPCN)|By:, SA News Editor

Lipocine (LPCN -10.3%) is down on a 5x surge in volume ahead of next Wednesday's FDA Ad Com review for oral testosterone replacement therapy TLANDO (testosterone undecanoate).

The day before, the advisory committee plans to discuss Clarus Therapeutics' application for JATENZO (testosterone undecanoate) for the same indication.

Previously: Ad Com next week for Clarus Therapeutics' oral testosterone (Jan. 5)